Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Capital Expenditures (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Capital Expenditures for 4 consecutive years, with $320000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures fell 55.8% to $320000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $320000.0 through Dec 2025, down 85.25% year-over-year, with the annual reading at $320000.0 for FY2025, 85.25% down from the prior year.
  • Capital Expenditures for Q3 2025 was $320000.0 at Day One Biopharmaceuticals, up from -$317000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $1.4 million in Q4 2024, with the low at -$317000.0 in Q2 2025.
  • Average Capital Expenditures over 4 years is $193461.5, with a median of $26000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures skyrocketed 2028.57% in 2023, then crashed 1319.23% in 2025.
  • Over 4 years, Capital Expenditures stood at $4000.0 in 2022, then crashed by 5500.0% to -$216000.0 in 2023, then surged by 756.94% to $1.4 million in 2024, then plummeted by 77.45% to $320000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $320000.0, -$317000.0, and $317000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.